US Bancorp
AIMT

US Bancorp’s Aimmune Therapeutics AIMT Stock Holding History

US Bancorp’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,214
Closed -$104K – 3934
2020
Q2 		$104K Sell
6,214
-8
-0.1% -$136 ﹤0.01% 2087
2020
Q1 		$90K Buy
6,222
+1,158
+23% +$29.6K ﹤0.01% 2076
2019
Q4 		$169K Buy
5,064
+1,554
+44% +$43.4K ﹤0.01% 1921
2019
Q3 		$73K Buy
+3,510
New +$71.7K ﹤0.01% 2301
2019
Q1 		– Sell
-1,616
Closed -$39K – 3700
2018
Q4 		$39K Hold
1,616
– – ﹤0.01% 2562
2018
Q3 		$44K Hold
1,616
– – ﹤0.01% 2634
2018
Q2 		$43K Hold
1,616
– – ﹤0.01% 2653
2018
Q1 		$51K Hold
1,616
– – ﹤0.01% 2609
2017
Q4 		$61K Buy
+1,616
New +$52.1K ﹤0.01% 2505

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

US Bancorp's AIMT Position: Q3 2020 in Review

US Bancorp sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 6,214 shares — an estimated $104K sold.

US Bancorp first reported a position in AIMT in Q4 2017 and held it in 9 quarters. The position peaked at $169K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • US Bancorp reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • US Bancorp sold 6,214 Aimmune Therapeutics shares in Q3 2020, an estimated $104K.
  • US Bancorp first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 9 quarters.
  • US Bancorp's Aimmune Therapeutics position peaked at $169K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on US Bancorp's 13F filing for Q3 2020, filed 10 Nov 2020.